Mesenchymal stem cells do not prevent antibody responses against human α-L-iduronidase when used to treat mucopolysaccharidosis type I.

Mucopolysaccharidosis type I (MPSI) is an autosomal recessive disease that leads to systemic lysosomal storage, which is caused by the absence of α-L-iduronidase (IDUA). Enzyme replacement therapy is recognized as the best therapeutic option for MPSI; however, high titers of anti-IDUA antibody have...

Full description

Bibliographic Details
Main Authors: Priscila Keiko Matsumoto Martin, Roberta Sessa Stilhano, Vivian Yochiko Samoto, Christina Maeda Takiya, Giovani Bravin Peres, Yara Maria Correa da Silva Michelacci, Flavia Helena da Silva, Vanessa Gonçalves Pereira, Vânia D'Almeida, Fabio Luiz Navarro Marques, Andreia Hanada Otake, Roger Chammas, Sang Won Han
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2014-01-01
Series:PLoS ONE
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24642723/pdf/?tool=EBI